Cargando…

Can Naloxegol Therapy Improve Quality of Life in Patients with Advanced Cancer?

SIMPLE SUMMARY: The frequent use of opioid in-home palliative care settings is associated with a high incidence of opioid-induced constipation (OIC) that can significantly worsen a cancer patient’s quality of life. Laxative therapy is the first-line in OIC treatment, and although its application is...

Descripción completa

Detalles Bibliográficos
Autores principales: Ostan, Rita, Gambino, Giuseppe, Malavasi, Italo, Ronga, Gianluca, Solipaca, Maria, Spunghi, Michela, Varani, Silvia, Pannuti, Raffaella, Ruggeri, Enrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616145/
https://www.ncbi.nlm.nih.gov/pubmed/34830889
http://dx.doi.org/10.3390/cancers13225736
_version_ 1784604277161852928
author Ostan, Rita
Gambino, Giuseppe
Malavasi, Italo
Ronga, Gianluca
Solipaca, Maria
Spunghi, Michela
Varani, Silvia
Pannuti, Raffaella
Ruggeri, Enrico
author_facet Ostan, Rita
Gambino, Giuseppe
Malavasi, Italo
Ronga, Gianluca
Solipaca, Maria
Spunghi, Michela
Varani, Silvia
Pannuti, Raffaella
Ruggeri, Enrico
author_sort Ostan, Rita
collection PubMed
description SIMPLE SUMMARY: The frequent use of opioid in-home palliative care settings is associated with a high incidence of opioid-induced constipation (OIC) that can significantly worsen a cancer patient’s quality of life. Laxative therapy is the first-line in OIC treatment, and although its application is recommended from the beginning of opioid therapy, in most cases it does not resolve the symptoms. Naloxegol is the specific target therapy for opioid-induced constipation. To our knowledge this is the first study aimed at evaluating the impact of a naloxegol therapy on the quality of life of advanced cancer patients with a short or very short life expectancy in a home palliative setting. ABSTRACT: This observational study aims to evaluate the efficacy of naloxegol therapy in resolving opioid-induced constipation (OIC) and in improving the quality of life in a home palliative care cancer setting. Advanced cancer patients with OIC (Rome IV criteria) not relieved by laxatives started a naloxegol therapy 25 mg/day for 4 weeks. Quality of life was evaluated by Patient Assessment of Constipation Quality-of-Life (PAC-QoL) at day 0 and day 28; background pain by Numerical Rating Scale, number of weekly spontaneous bowel movements and Bowel Function Index (BFI) were evaluated at day 0 and every week. Seventy-eight patients who completed the 4-week study improved all four PAC-QoL dimensions (physical and psychological discomfort, worries/concerns and satisfaction level). Weekly spontaneous bowel movements increased and BFI improved. Background pain reduced after seven days and remained lower during the following weeks. Seventy-two patients dropped out the study before day 28 with a reduced survival compared to patients completing the study. Even in these patients, an improvement of bowel function was observed after two weeks. Naloxegol was effective in improving the quality of life, resolving OIC and reducing overall pain in patients with advanced cancer.
format Online
Article
Text
id pubmed-8616145
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86161452021-11-26 Can Naloxegol Therapy Improve Quality of Life in Patients with Advanced Cancer? Ostan, Rita Gambino, Giuseppe Malavasi, Italo Ronga, Gianluca Solipaca, Maria Spunghi, Michela Varani, Silvia Pannuti, Raffaella Ruggeri, Enrico Cancers (Basel) Article SIMPLE SUMMARY: The frequent use of opioid in-home palliative care settings is associated with a high incidence of opioid-induced constipation (OIC) that can significantly worsen a cancer patient’s quality of life. Laxative therapy is the first-line in OIC treatment, and although its application is recommended from the beginning of opioid therapy, in most cases it does not resolve the symptoms. Naloxegol is the specific target therapy for opioid-induced constipation. To our knowledge this is the first study aimed at evaluating the impact of a naloxegol therapy on the quality of life of advanced cancer patients with a short or very short life expectancy in a home palliative setting. ABSTRACT: This observational study aims to evaluate the efficacy of naloxegol therapy in resolving opioid-induced constipation (OIC) and in improving the quality of life in a home palliative care cancer setting. Advanced cancer patients with OIC (Rome IV criteria) not relieved by laxatives started a naloxegol therapy 25 mg/day for 4 weeks. Quality of life was evaluated by Patient Assessment of Constipation Quality-of-Life (PAC-QoL) at day 0 and day 28; background pain by Numerical Rating Scale, number of weekly spontaneous bowel movements and Bowel Function Index (BFI) were evaluated at day 0 and every week. Seventy-eight patients who completed the 4-week study improved all four PAC-QoL dimensions (physical and psychological discomfort, worries/concerns and satisfaction level). Weekly spontaneous bowel movements increased and BFI improved. Background pain reduced after seven days and remained lower during the following weeks. Seventy-two patients dropped out the study before day 28 with a reduced survival compared to patients completing the study. Even in these patients, an improvement of bowel function was observed after two weeks. Naloxegol was effective in improving the quality of life, resolving OIC and reducing overall pain in patients with advanced cancer. MDPI 2021-11-16 /pmc/articles/PMC8616145/ /pubmed/34830889 http://dx.doi.org/10.3390/cancers13225736 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ostan, Rita
Gambino, Giuseppe
Malavasi, Italo
Ronga, Gianluca
Solipaca, Maria
Spunghi, Michela
Varani, Silvia
Pannuti, Raffaella
Ruggeri, Enrico
Can Naloxegol Therapy Improve Quality of Life in Patients with Advanced Cancer?
title Can Naloxegol Therapy Improve Quality of Life in Patients with Advanced Cancer?
title_full Can Naloxegol Therapy Improve Quality of Life in Patients with Advanced Cancer?
title_fullStr Can Naloxegol Therapy Improve Quality of Life in Patients with Advanced Cancer?
title_full_unstemmed Can Naloxegol Therapy Improve Quality of Life in Patients with Advanced Cancer?
title_short Can Naloxegol Therapy Improve Quality of Life in Patients with Advanced Cancer?
title_sort can naloxegol therapy improve quality of life in patients with advanced cancer?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616145/
https://www.ncbi.nlm.nih.gov/pubmed/34830889
http://dx.doi.org/10.3390/cancers13225736
work_keys_str_mv AT ostanrita cannaloxegoltherapyimprovequalityoflifeinpatientswithadvancedcancer
AT gambinogiuseppe cannaloxegoltherapyimprovequalityoflifeinpatientswithadvancedcancer
AT malavasiitalo cannaloxegoltherapyimprovequalityoflifeinpatientswithadvancedcancer
AT rongagianluca cannaloxegoltherapyimprovequalityoflifeinpatientswithadvancedcancer
AT solipacamaria cannaloxegoltherapyimprovequalityoflifeinpatientswithadvancedcancer
AT spunghimichela cannaloxegoltherapyimprovequalityoflifeinpatientswithadvancedcancer
AT varanisilvia cannaloxegoltherapyimprovequalityoflifeinpatientswithadvancedcancer
AT pannutiraffaella cannaloxegoltherapyimprovequalityoflifeinpatientswithadvancedcancer
AT ruggerienrico cannaloxegoltherapyimprovequalityoflifeinpatientswithadvancedcancer